A concise analysis of innovative anticancer drugs approved by FDA in 1999-2014Alita, WU Zhi-ang1081-1090
The lesson of failure is more reliable than successful experience in developing new drugsLI Feng-jie, LI Lian-da, LI Yi-kui1091-1092
Inspiration of India "Delhi" mode to realize the goals of national essential drug systemWANG Dan-ping1093-1095
Systematic introduction about clinical research management of HMS DF/HCC: entire process management of clinical researchCAO Ye1096-1099
Development and suggestion of biosimilar monoclonal antibodyWANG You-fu, YUAN Xi-bin, ZHANG Juan1100-1104
Key technical points in clinical trial design of the new drugs of traditional Chinese medicine for the treatment of strokeLIU Bing-lin1105-1107,1127
Influences on intestinal absorption of (-)-Syringaresinol-4-O-β-D-apiofuranosyl-(1→2)-β-D-glucopyranoside in a rat model of in situ single-pass perfusionHUANG Hai-ying, GUO Yan-li, HE Yuan-song, WU Min-xuan, LI Jian, YU Ding-rong, SHI Jin-li1108-1112
Preparation and accelerated release test of ropivacaine mesilate micropheresZHAO Xi-qing, LI Zhi-ping, ZHAO Shi-qing, LIU Yan, XIAO Ruo-lei, MEI Xing-guo1113-1118
Target identification of bioactive small moleculesWANG Dong-yao, CHEN Xiao-fei, CAO Yan, ZHU Zhen-yu, ZHANG Jun-ping, CHAI Yi-feng1119-1123
Advances in application of articular cavity microdialysis in pharmacokinetics and pharmacodynamicsSHAN Lian-ju, DING Han-ying, WANG Rui, LI Yong-ji1124-1127